[Current status and prospects of immunotherapy for castration-resistant prostate cancer]

Junji Yatsuda, Masatoshi Eto

Research output: Contribution to journalArticle

Abstract

Surgery, radiation and chemotherapy are three major therapies for cancer. But now, hope is being gathered in immunotherapy as a treatment for fourth. Immunotherapy has been done than before, but they are non-specific immunotherapy. Those that have become hot topics are specific immunotherapies targeting certain molecules or antigens. In this chapter, current status and prospects of immunotherapy for castration-resistant prostate cancer (CRPC) are described. As concrete examples, Sipuleucel-T(Provenge), GVAX, PROSTVAC-VF, Ipilimumab (anti-CTLA-4 mAb), anti-PD-1 mAb and anti-PSMA mAb are cited. As a result, it is not obtained results which therapy also satisfactory at present. Because of its uncertainties we are in the developmental stages of this therapy and improved outcomes might be achievable.

Original languageEnglish
Pages (from-to)2174-2178
Number of pages5
JournalNihon rinsho. Japanese journal of clinical medicine
Volume72
Issue number12
Publication statusPublished - Dec 1 2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of '[Current status and prospects of immunotherapy for castration-resistant prostate cancer]'. Together they form a unique fingerprint.

  • Cite this